---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019374"
form_type: "8-K"
ticker: null
cik: "0001733294"
company_name: "Generation Bio Co."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:21:49.624636+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Generation Bio cuts 40% of workforce, extends cash runway to 2H 2027

## Summary
- Workforce reduction of ~40% approved Nov 27; expected cost savings of ~$120M over three years.
- Cash runway extended into second half of 2027 due to reorganization and reduced operational spend.
- CMO Douglas Kerr and CDO Tracy Zimmermann to depart Jan 28, 2024; severance total $0.7M plus accelerated equity.
- Severance and retention costs estimated $7-8M, recognized in Q4 2023 and Q1 2024.
- Company prioritizes ctLNP delivery for extrahepatic cell types and iqDNA platform for hemophilia A.

## SEC filing metadata
- accession: 0001558370-23-019374
- form_type: 8-K
- cik: 0001733294
- company_name: Generation Bio Co.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733294/000155837023019374/0001558370-23-019374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733294/000155837023019374/gbio-20231127x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019374
- JSON: https://secwatch.observer/filing/0001558370-23-019374.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019374.txt

## Key facts
- Executive change
  Douglas Kerr was terminated as Chief Medical Officer at Generation Bio Co..
  - Action: terminated
  - Role: Chief Medical Officer
  source text: As part of the RIF described above in Item 2.05, the Company will terminate the employment of Douglas Kerr, M.D., Ph.D., M.B.A., the Company’s Chief Medical Officer, and Tracy Zimmermann, Ph.D., the Company’s Chief Development Officer, effective as of January 28, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733294/000155837023019374/0001558370-23-019374-index.htm
- Executive change
  Tracy Zimmermann was terminated as Chief Development Officer at Generation Bio Co..
  - Action: terminated
  - Role: Chief Development Officer
  source text: As part of the RIF described above in Item 2.05, the Company will terminate the employment of Douglas Kerr, M.D., Ph.D., M.B.A., the Company’s Chief Medical Officer, and Tracy Zimmermann, Ph.D., the Company’s Chief Development Officer, effective as of January 28, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733294/000155837023019374/0001558370-23-019374-index.htm
- Restructurings & Charges
  Generation Bio Co. announced a restructuring with charges of approximately $7 million to $8 million (approximately 40%).
  - Type: restructuring
  - Charge: approximately $7 million to $8 million
  - Headcount: approximately 40%
  source text: the Company estimates that it will incur severance-, termination- and retention-related costs of approximately $7 million to $8 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733294/000155837023019374/0001558370-23-019374-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.